Clinical Trials Browser

Phase 1/2 × Withdrawn × ADI PEG20 × Clear all

NCT06006286 2024-08-26

A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma

Phase 1/2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular